A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Open accessThe DOI matches its Crossref record; 121 of the 127 references it cites were found in a registry or an index; 18 of the 86 sources its claims cite were checked for support.
Abstract
The process of stopping antipsychotics may be causally related to relapse, potentially linked to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity. Therefore, the risk of relapse on cessation of antipsychotics may be minimized by more gradual tapering. There is converging evidence that suggests that adaptations to antipsychotic exposure can persist for months or years after stopping the medication-from animal studies, observation of tardive dyskinesia in patients, and the clustering of relapses in this time period after the cessation of antipsychotics. Furthermore, PET imaging demonstrates a hyperbolic relationship between doses of antipsychotic and D2 receptor blockade. We, therefore, suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): ie, reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance. Some patients may prefer to taper at 10% or less of their most recent dose each month. This process might allow underlying adaptations time to resolve, possibly reducing the risk of relapse on discontinuation. Final doses before complete cessation may need to be as small as 1/40th a therapeutic dose to prevent a large decrease in D2 blockade when stopped. This proposal should be tested in randomized controlled trials.
Overview
CoChat Summary
TL;DR
The paper proposes that antipsychotics should be tapered gradually over months or years and in a hyperbolic manner—reducing by fractions of the most recent dose that correspond to roughly even decrements in D2 receptor blockade—to minimize withdrawal-related relapse. It argues this hypothesis is supported by converging evidence on dopamine supersensitivity, tardive dyskinesia, relapse clustering after cessation, and PET dose-occupancy relationships, but it has not been tested in randomized controlled trials.
Key findings
- The authors recommend reductions of one quarter or one half of the most recent antipsychotic dose, approximately equivalent to 5 or 10 percentage-point reductions in D2 blockade, at intervals of 3–6 months, titrated to individual tolerance; some patients may prefer reductions of 10% or less of the most recent dose each month.
- Final doses before complete cessation may need to be as small as 1/40th of a therapeutic dose to avoid a large drop in D2 blockade when stopped.
- A meta-analysis cited by the authors found relapse rates over the next year of 77% after abrupt stopping, 57% after stopping over 1–2 weeks, 47% after 3–10 weeks, and 31% after tapering longer than 10 weeks.
- PET data show a hyperbolic dose–D2 occupancy relationship; for haloperidol, linear dose reductions from 4 mg produce increasingly large occupancy drops: 3.5 percentage points from 4 to 3 mg, 6.1 from 3 to 2 mg, 13.7 from 2 to 1 mg, and 55.7 from 1 to 0 mg.
Methods
- Narrative review and hypothesis paper synthesizing animal studies, human PET imaging, case reports, observational studies, and randomized discontinuation trials; no new primary data are collected.
- The authors review relapse patterns after antipsychotic discontinuation, evidence on tardive dyskinesia and dopaminergic hypersensitivity, and PET-derived dose–D2 occupancy relationships.
- They use Emax equations of the form y = maximal occupancy × x/(x + ED50) to derive hyperbolic tapering schedules for six antipsychotics, with doses rounded and intended to be individualized.
Limitations
- The paper states that PET studies have relatively small sample sizes and may not capture individual variation, though the hyperbolic shape of the dose–activity curve is expected to be universal; heterogeneity in PET meta-analyses suggests interindividual differences in receptor occupancy for a given dose.
- The paper states that it is difficult to determine whether D2 occupancy linearly corresponds to withdrawal effects, and that other receptor targets such as 5HT2, 5HT1A, and cholinergic receptors may also determine withdrawal effects, particularly for clozapine.
- The text makes evident that the proposed tapering method is a hypothesis not yet tested in randomized controlled trials; the authors explicitly state that it should be tested in further tapering trials, and the figures’ time frames are described as theoretical, based on few small studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
14 Valid · 3 Not valid · 35 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis in Patients With Schizophrenia
What the sources say
- Not checked — no full text of the sourcecites [3] Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997; 54(1): 49– 55. 9006400 source
- Not checked — no full text of the sourcecites [56] Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379(9831): 2063– 2071. 22560607 source
- Not checked — no full text of the sourcecites [57] Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013; 70(9): 913– 920. 23824214 source
- Not checked — no full text of the sourcecites [58] Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry.. 2016; 77(4): 492– 500. 26759992 source
- Disputedcites [59] Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010; 341: c4024. 20724402 PMC2924475 sourceExperimental — accuracy not yet measured
The Results (Primary outcome: relapse; page not provided) report that only 23 of 83 relapses occurred within 60 days of randomisation; 60 occurred later. The Methods (Statistical analysis; page not provided) identify those first 60 days as the period when relapse might be related to switching medication. The reported relapses therefore did not occur predominantly around drug cessation. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [7] Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med. 2015; 12(8): e1001861. 26241954 PMC4524699 sourceExperimental — accuracy not yet measured
The Evidence for Maintenance Therapy section says antipsychotic withdrawal may make relapse more likely in people with schizophrenia. It does not describe persistently increased presynaptic DSC or an interaction with elevated postsynaptic sensitivity; searches for those mechanisms found no supporting passage. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [23] Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017; 86(4): 189– 219. 28647739 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Meta-analysis of molecular imaging studies in schizophrenia found increased D2/D3 receptor availability only in those subjects who had been exposed to antipsychotic medication but not in antipsychotic-naïve patients.38”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [38] Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69(8): 776– 786. 22474070 PMC3730746 source
The Dopamine receptors section (p. 6) reports a significant difference in D2/3 receptor availability in studies including previously treated patients, but no significant difference in studies exclusively of antipsychotic-naïve patients. The Methodological considerations section (p. 8) likewise says the small elevation was not present in drug-naïve patients, while cautioning that those analyses had reduced power. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Schizophrenia is attributed to increased presynaptic dopaminergic synthesizing capacity (DSC)54”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [54] McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018; 44(6): 1301– 1311. 29301039 PMC5933516 sourceExperimental — accuracy not yet measured
The Results (Studies of the Whole Striatum; page unavailable) report elevated presynaptic dopamine function in people with schizophrenia, including a significant elevation in studies using labeled L-DOPA. But the paper does not establish that increased dopamine synthesis capacity causes schizophrenia; the Discussion (The Anatomical Locus of Dopaminergic Dysfunction in Psychosis; page unavailable) says causality remains to be established. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In animals, dopaminergic blockade leads to dopaminergic hypersensitivity.35,36”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [35] Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007; 27(11): 2979– 2986. 17360921 PMC6672560 source
The Introduction describes antipsychotics as antidopaminergic treatment and reports increased responses to dopamine agonists in laboratory animals after chronic treatment. The Discussion also reports dopamine supersensitivity during ongoing haloperidol treatment in animals. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [36] Joyce J. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 2001; 40: 137– 144. 11252025 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
41 more claims · 6 with their cited sources checked
Create a free account to see all 71 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Horowitz-Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,9,15”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredIn the citing paper
“The Horowitz–Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,11,13”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Table: Table 1. Case studies reporting psychotic symptoms following abrupt cessation of dopamine antagonists prescribed for reasons other than treating psychosis in patients with no history of primary psychotic symptoms”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Eight case reports describe psychotic symptoms arising in 13 patients with no history of psychosis after the abrupt withdrawal of dopamine antagonists (table 1).”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“26 M BPAD with brief DIP and no other psychotic symptoms | Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“Table: Table 2 Randomized controlled trials examining discontinuation (DS) groups vs maintained (MT) groups (n.s. = no significant difference; N/A = not available)”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“however, this last study was not randomized, meaning selection bias is possible”
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Self-citationHowes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
Research works printed but not linked: 3
- McGorry P, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry. 2013; 70(9): 898– 900. 23824206 · DOI · Paper page
- Seeman P. Yes, Breast is best but taper domperidone when stopping (e-letter). Br J Gen Pract. 2014. https://bjgp.org/content/yes-breast-best-taper-domperidone-when-stopping. Accessed 21 January 2020.
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of partients with schizophrenia. Am J Psychiatry. 2004; 161(2 SUPPL): 1– 56. 15000267
Cited by
Items 101–154 of 154
Orlando, S., Long, M., Akther-Robertson, J., Stansfeld, J. L., Haime, Z., Smith, R., Moncrieff, J., & Morant, N. J. (2025) · Journal of Mental Health · doi:10.1080/09638237.2025.2585195 · Cited by 1
“Antipsychotic reduction that is gradual and clinically guided may have relatively lower relapse risks (Horowitz et al., 2021) and encourage a greater sense of agency and involvement in service users (Mølgaard et al., 2024).”
Hidding, M., van der Stouwe, E. C. D., Rosema, B., Begemann, M., de Haan, L., van Os, J., Koops, S., Wijnen, B. F. M., Boonstra, N., & Veling, W. (2025) · Psychological Medicine · doi:10.1017/s0033291725102857 · Cited by 1
“Although some participants maintained their medication dosage, individuals can adapt to medications over time or switch to a different medication, which could have influenced the results (Horowitz et al., 2021).”
Hui, C. L. M., Wong, C. C. L., Yang, N. C. L., Choi, E. G., Hui, P. W. M., Lui, E., Tao, J., Ho, E. C., Suen, Y. N., Chen, S., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02185-8 · Cited by 1
“Abrupt versus tapered discontinuation may also differentially affect DSC and relapse risk [34 ].”
Eserian, J. K., de Oliveira, F. F., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10663 · Cited by 1
Absolute Receptor Occupancy, Not Rate of Decline, Predicts Relapse
McCutcheon, R. A., Pillinger, T., Rubio, J. M., Taylor, D. M., & Jauhar, S. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag057 · Cited by 1
Self-citationHorowitz, M. A. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf256 · Cited by 1
Self-citationLouie, K., Jauhar, S., Rubio, J., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00225-7 · Cited by 2
Self-citationJoo, S. W., Kim, H., Jo, Y. T., Ahn, S., Choi, Y. J., Choi, W., Park, S., & Lee, J. S. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13341 · Cited by 1
“A recent study by Horowitz et al.(7) proposed a method for tapering antipsychotic dose to minimize the risk of relapse on the consideration of relationships between antipsychotic dose and D2 receptor occupancy, emphasizing prolonged tapering in contrast to abrupt cessation.”
MethodInfluentialSutjiono, B., Ahmad, S. F., & Jaya, E. S. (2022) · Behaviour Change · doi:10.1017/bec.2022.11 · Cited by 1
Online Control for Adaptive Tapering of Medications
Gradu, P., & Recht, B. (2023) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc49753.2023.10384168 · Cited by 2
“Horowitz et al. [3], [4] propose a similar method (very slow, hyperbolic) for tapering of antipsychotic medication.”
MethodThe impact of fluphenazine withdrawal: a mirror-image study
Meehan, S., Moran, S., Rainford, A., McDonald, C., & Hallahan, B. P. (2024) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2024.2 · Cited by 1
“…exposure have been purported to persist for many months or years after stopping antipsychotics, and consequently tapering of antipsychotics and in particular highly potent dopamine 2 antagonists (i.e. fluphenazine) has been suggested to require a very gradual process (Horowitz et al., 2023).”
BackgroundDrug Treatment of the Psychoses
Rogers, J. P., Chesney, E., Morrison, P., & Gaughran, F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.012 · Cited by 3
Maviglia, M. A., Cooeyate, N. J., Hume, D., & Guerra, L. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00793 · Cited by 1
Koch, T., von Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116685 · Cited by 1
“This stands in contrast to the general absence of clear recommendations and guidelines for how to reduce/discontinue both AD and AP properly, as indicated in the literature (Horowitz et al., 2021; Jauhar et al., 2023; McCutcheon et al., 2024; Sørensen et al., 2022a; Zwiebel and Viguera, 2022).”
Stupak, R. (2021) · Praktyka Teoretyczna · doi:10.14746/prt.2021.2.6 · Cited by 1
Maintenance antipsychotic trials and the effect of withdrawal – Authors' reply
Schneider‐Thoma, J., Siafis, S., & Leucht, S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01442-8 · Cited by 1
Louie, K., Jauhar, S., Rubio, J. M., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · medRxiv · doi:10.64898/2026.01.19.26344378 · Cited by 1
Self-citationAbie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251371504
Self-citationCase Presentation: Iatrogenic Psychosis
Fariba, K. (2021) · doi:10.53902/jpssr.2021.01.000522
Meyer, J. M., & Stahl, S. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781009002103.006
Takeuchi, H., & Watabe, K. (2022) · Research Square · doi:10.21203/rs.3.rs-2146246/v1
Current treatment options in early-onset psychosis
Pagsberg, A. K., & Melau, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89832-4.00002-0
Anesthetic Concerns in Psychiatric Disease
Martinez-Baladejo, M. T., Liongson, F. A. Z., Wong, D., Spoleti, C., Suyumov, D., Menghani, S. V., McCarthy, C., Divito, A. J., Daniel, S. V., Salpekar, S., et al. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110173 · Cited by 2
Hasler, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839445716 · Cited by 3
Chapter 53. Treatment of Schizophrenia
Brunette, M. F., Ballon, J. S., Gnanasegaram, S. A., Kalinowski, A., Keller, W. R., Reed, J. D., & Noordsy, D. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as53
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00003-9
Antipsychotic Deprescribing Analyzed as a Wicked Problem
Ustrup, M., Roe, D., & Speyer, H. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251328088 · Cited by 3
Yen, K., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., Liu, C.-I., & Liu, C.-C. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104534
Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysis
O’Neill, J. R., Sørensen, A., Taylor, D. M., & Horowitz, M. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120084 · Cited by 2
Self-citationKumar, A., Keerikkadu, M., Bangera, P. D., Shetty, A., Tippavajhala, V. K., & Rathnanand, M. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2579655 · Cited by 1
“Most of the schizophrenic patients require long-term therapy, and even if the symptoms sub-sided, the treatment needs to be continued, or some-times there will be chances of withdrawal symptoms or relapse when the antipsychotics are stopped abruptly [5].”
Ruiz‐Pérez, G., Ulrich, N., Bettin, J., Lippert, J., Koch, T., & von Peter, S. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01922-7
“Auf internationaler Ebene finden sich wissenschaftliche Artikel, die praktische Strategien zum R&A darstellen [10, 24, 26].”
Kane, J. M., Tohami, O., Franzenburg, K. R., Suett, M., Sharon, N. A., Wagner, A. M., Eshet, R., Harary, E., & Correll, C. U. (2025) · CNS Drugs · doi:10.1007/s40263-025-01240-1
“Because of abrupt cessation of oral antipsychotic treatment, those patients randomized to placebo in stage 2 may have been more prone to relapse or worsening of symptoms [76, 77].”
Antipsychotics in combination with central stimulants
Jacobsen, M., Strand, N. A. W., Bøgevig, S., & Nielsen, J. (2025) · Ugeskrift for Læger · doi:10.61409/v02250074
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v1
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v2
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v3
Psychotropes et personnalité borderline : prescrire, ne pas prescrire, déprescrire ?
Berna, F. S., Musso, M., Weibel, S., & Brunn, M. (2026) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2026.03.011 · Cited by 1
Antipsychotic effects of aqueous lyophilisate of Ficus mucuso on ketamine-induced schizophrenia
Moto, F. C. O., DIAPA, J. T., Njapdounké, J. S. K., Mbom, A., Savo, F. M., Aren, M. N. A., Nezoumne, F. N., Ndjock, R. S., & Bum, E. N. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1788148
“In addition to the use of antipsychotic drugs to treat schizophrenia (23), plants are now considered an alternative and maintenance treatment due to their availability and low cost (24), as well as their ability to alleviate schizophrenia with few or no adverse effects.”
Moncrieff, J., Long, M., Priebe, S., Akther-Robertson, J., Barnes, T. R. E., Bray, G., Cooper, R. E., Crellin, N. E., Darton, K., Freemantle, N., et al. (2026) · Programme Grants for Applied Research · doi:10.3310/gjjm0506
Self-citationFerreira, P. M., McDonald, S., Wallis, K. A., & Donald, M. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116702 · Cited by 1
Berna, F. S., Horowitz, M. A., Javelot, H., Meyer, N., & Foucher, J. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-117593 · Cited by 2
“Horowitz et al 13 have proposed psychopharmacology-driven tapering schemas to best minimise both the risk of relapse and that of supersensitivity psychosis in SSD patients.”
InfluentialSelf-citationKoch, T., Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00583-5
Atuação do profissional farmacêutico no processo de desmame de benzodiazepínicos
de Oliveira, M. V., Arcanjo, M. L. M., & Santos, C. C. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51363
Expert Consensus on the Use of Lurasidone for Bipolar I Depression in Asian Patients
Sulaiman, A. H., Chui, M.-C. E., Kongsakon, R., Lee, J. P., Lin, C., Ng, B. Y., Tan, M. W. L., Ting, J. H., & Idris, M. H. M. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap49358
Mind and body: mental illness as an “invisible” or hidden condition
Shan), L. S. C. (. L. (2026) · Journal of Public Mental Health · doi:10.1108/jpmh-05-2026-0128
Fargier, P.-B., Horowitz, M. A., CHARLES, R., Rousselon, V., Fakra, É., Beyens, M., & Laroche, M. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70278 · Cited by 1
“However, recent literature has increasingly questioned these empirical protocols, instead advocating alternative approaches, such as hyperbolic tapering of psychotropics in adults [20, 21].”
InfluentialSelf-citationMuraoka, H., Momohara, S., & Inada, K. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100346
Déprescription des antipsychotiques : psychiatres, qu’en pensez-vous ?
Calligaris, T., Queuille, E., Debruyne, A.-L., Colombe, A., & Quilès, C. (2026) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2026.06.010
Focused review: Clozapine safety and effects on pancreatitis
Cuevas, C. D. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00013-0
Relapse or rebound: the case for personalisation in antipsychotic discontinuation
Krishnadas, R., & Smitha, C. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00270-1
Jivraj, K., Gault, I., & Chambers, M. (2026) · Health Expectations · doi:10.1111/hex.70828
“However, some SUs reported they would have liked but did not receive support for this, reinforcing the need for clearer guidance on withdrawal and long‐term treatment effects [63, 64].”
Antipsychotic Use in Pediatric Posttraumatic Stress Disorder and Trauma-Related Disorders
Saleh, A., Trojanowski, B., Hamati, F., & Feder, J. D. (2026) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2026.07.003
Metadata
- Authors
- Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D.
- Affiliations
- Goodmayes Hospital (GB)
- King's College London (GB)
- Corresponding author
- Horowitz, Mark Abie
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-23
- Volume
- 47
- Issue
- 4
- Pages
- 1116-1129
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC8266572
- OpenAlex
- W3137682600
- Semantic Scholar
- a855858cd020d93218767ac4e43fbf07848933a0
- Cited by
- 157
- References
- 127
- Citations by year
- 2026: 28 · 2025: 33 · 2024: 24 · 2023: 32 · 2022: 24 · 2021: 15
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Funders
- North East London NHS Foundation Trust
- Royal College of Physicians of Edinburgh
- National Institute for Health Research Biomedical Research Centre
- South London and Maudsley NHS Foundation Trust
- King’s College London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- antipsychotic tapering, antipsychotic discontinuation
- MeSH terms
- Drug Administration Schedule, Female, Humans, Male, Recurrence, Schizophrenia, Antipsychotic Agents, Risk Assessment, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.